Phase 3 trial to assess M72/AS01E-4 Mycobacterium tuberculosis (TB) vaccine - Grants Awarded

This website will not work correctly in Internet Explorer 11 and it is strongly recommended that you upgrade to an up-to-date browser. Internet Explorer 11 will go out of support and be retired on June 15, 2022. For more information on upgrading please see browser-update.org.

Discretionary Award

Year of award: 2023

Dr Emilio Emini
Gates Medical Research Institute, United States
PATRICE MATCHABA
Bill & Melinda Gates Foundation, United States

A Phase 3, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0-,1-month schedule to adolescents and adults.

Share this page

Grantholders

Dr Emilio Emini

PATRICE MATCHABA

Project summary